Vyriad was founded by Stephen J. Russell, MD, PhD, Kah-Whye Peng, PhD, Stephen J. Russell, Kah-Whye Peng.

Who are Vyriad's investors?

Vyriad's investors include Southeast Minnesota Capital Fund.

How much funding has Vyriad raised?

Vyriad has disclosed $49.4M raised across 2 of its 5 known rounds.

Where is Vyriad headquartered?

Vyriad is headquartered in Rochester, US.

Vyriad

Rochester, US · Delaware corporation · 3 known investors

Find your way into Vyriad

Each arrow is one introduction. Sign up to fill in the first one.

222 people can intro you to Luke

Ask David Cohn to introduce you to Luke Russell

You →David · together at Ohio State University Comprehensive Cancer Center-James Cancer Hospital & Solove Research Institute →Luke

136 people can intro you to Alice

Ask Jamie Chen to introduce you to Alice S. Bexon

You →Jamie · together at Idera Pharmaceuticals →Alice

76 people can intro you to Roger

Ask Sam Okafor to introduce you to Roger A. Lindahl

You →Sam · together at Honeywell Inc. →Roger

Your email: who you already know at Vyriad, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Vyriad team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Vyriad is a clinical-stage biotechnology company developing oncolytic virus-based therapies for cancer treatment. It works on engineering viral cancer immunotherapies and GMP virus manufacturing, and has pharma partnerships with companies including Novartis, Regeneron, and Merck KGaA.

Biotech Healthtech Medical Devices

Founders & leadership

Stephen J. Russell, MD, PhDCo-founder

Kah-Whye Peng, PhDCo-founder

Stephen J. RussellExecutive Chairman and Chief Scientific Officer, Co-founder

Kah-Whye PengCo-Founder and Chief Technical Officer

Luke Russell PresidentLuke Russell is President of Vyriad, a clinical-stage biotechnology company developing oncolytic virus-based therapies for cancer treatment.

Alice S. Bexon Chief Medical OfficerAlice S. Bexon is Chief Medical Officer at Vyriad, a clinical-stage biotech company developing oncolytic virus therapies for cancer. She brings experience in clinical development, regulatory strategy, and medical oversight across oncology, ophthalmology, infectious disease, and other therapeutic areas.

Roger A. Lindahl Chief Financial OfficerChief Financial Officer of Vyriad, a clinical-stage biotechnology company developing oncolytic virus-based immunotherapies. Lindahl brings extensive financial leadership experience including monthly accounting close, financial reporting, GAAP and IFRS compliance, budgeting, and enterprise resource planning systems implementation.

James HannonNamed on SEC filing

Glen N. BarberNamed on SEC filing

Ahryon Cho Member Board Of Directors2017–2021Regional Head, JLABS Korea at Johnson & Johnson Innovation – JJDC

Andrew KhooNamed on SEC filing

Nathan L. StacyNamed on SEC filing

Investors · 3

Southeast Minnesota Capital Fundlisted by Southeast Minnesota Capital FundRochester

How we know: Southeast Minnesota Capital Fund's portfolio page · Not right? Tell us

Also in the syndicate · 2

Stine Seed Farms Inc.leadStine Seed Farms, Inc.lead

Funding

SEC filings, press & company announcements

$49.4M disclosed across 2 of 5 rounds · 2019–2026

$25MSeries BJan 2026 · 2 sources
Stine Seed Farms Inc. (lead)
Source ↗
Undisclosed amountSeries BDec 2025
Stine Seed Farms, Inc. (lead)
Source ↗
Undisclosed amountSeries BMay 2022
Source ↗

▶$24.4MraisedNov 2019 · 10 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Stephen J. Russell, MD, PhDExecutive Officer, Director, Promoter
Kah-Whye Peng, PhDExecutive Officer
James HannonExecutive Officer
Glen N. BarberDirector, Promoter
Ahryon ChoDirector
Andrew KhooDirector
Edwin M. Kania, Jr.Director
Nathan L. StacyDirector
Alice S. Bexon, MDExecutive Officer

Offering amount: $37.8M
Amount sold: $24.4M
First sale: Oct 2019
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 5

Myriad GeneticsMyriad Genetics is a genetic testing and precision medicine company that delivers molecular diagnostic test results across hereditary cancer risk, reproductive health, oncology, urology, and mental health. It serves patients and healthcare providers with insights to help detect, treat, and prevent disease.

American Cancer Society (ACS)The American Cancer Society is a nonprofit organization that provides cancer research updates, screening and prevention guidance, and community engagement opportunities. It serves individuals seeking cancer information and those who want to support cancer research and patient advocacy efforts.

CancerresearchukCancer Research UK funds research across discovery, detection, prevention and treatment of cancer to improve patient outcomes and extend survival. It operates as a research funder and scientific organization serving academic and clinical researchers.

Viridian TherapeuticsViridian Therapeutics develops treatments for thyroid eye disease, a rare autoimmune condition affecting the eyes and orbit. The company focuses on clinical development and patient support programs in the biotech sector.

Fred HutchFred Hutch is a cancer research institute that develops biomarkers, therapies, and stem cell products for research and clinical use, and provides data infrastructure and funding to commercialize discoveries into treatments and spinout companies.

Companies working in the same space as Vyriad.

In the news

Vyriad Begins Phase 1 Clinical Trial for Lead In Vivo CAR T Cell Therapy VV169 Following FDA Acceptance of IND Application - BioSpacebiospace.com · Sep 2026

Vyriad Raises Final $25M Series B Tranchefinsmes.com · Jan 2026

Frequently asked questions

What does Vyriad do?: Vyriad is a clinical-stage biotechnology company developing oncolytic virus-based therapies for cancer treatment. It works on engineering viral cancer immunotherapies and GMP virus manufacturing, and has pharma partnerships with companies including Novartis, Regeneron, and Merck KGaA.
Who founded Vyriad?: Vyriad was founded by Stephen J. Russell, MD, PhD, Kah-Whye Peng, PhD, Stephen J. Russell, Kah-Whye Peng.
Who are Vyriad's investors?: Vyriad's investors include Southeast Minnesota Capital Fund.
How much funding has Vyriad raised?: Vyriad has disclosed $49.4M raised across 2 of its 5 known rounds.
Where is Vyriad headquartered?: Vyriad is headquartered in Rochester, US.